Not Signed In - New Data On Investigational Agent TMC278 In Anitretroviral-Naive HIV Patients
Fri, 02 Mar 2007 08:00 AM EST
... Tibotec Pharmaceuticals Ltd. presented the first results of the phase 2b dose-finding study of TMC278 at the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles earlier this week. TMC278 is a next-generation investigational non- nucleoside reverse transcriptase inhibitor (NNRTI). It is currently being studied in treatment-naive HIV patients in phase 2. [click link for full article] ...
Related Topics
- Data & Statistics
- Agent Orange
- Chemical Agents
- Data Analysis
- HIV/AIDS & STDs
- National Data
- HIV Testing
- Vaccinations For HIV/AIDs Patients
- HIV Antibody
- Mining
- Migration
- Perinatal HIV
- Riot Control Agents
- Seizures (in about half of patients)
- Acquired Immune Deficiency Syndrome
- Healthcare Workers
- What Your Female Patients Want to Know About Bladder Control
- Smoking Cessation and Continued Risk in Cancer Patients
- Approximately one-half of patients with small tumors will get back useful hearing in the affected ear after surgery.
- Logging
email this page
print this page
bookmark this page
feedback on this page
